Cingulate Inc. (CING) - Q3 2025 10-Q Summary
Business Context and Reporting Period
Cingulate Inc. is a biopharmaceutical company developing once-daily, multi-dose tablet therapies for ADHD and anxiety using its Precision Timed Release (PTR) platform. The reporting period covers the three and nine months ended September 30, 2025. The Company is a pre-revenue entity with no approved products. Key milestones include the submission of a New Drug Application (NDA) for its lead asset, CTx-1301 (dexmethylphenidate), on July 31, 2025, with a PDUFA target action date of May 31, 2026.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(7.34)M | $(4.13)M | $(16.18)M | $(10.33)M |
| Operating Loss | $(6.00)M | $(3.28)M | $(14.35)M | $(9.44)M |
| R&D Expenses | $2.85M | $1.43M | $7.77M | $5.12M |
| G&A Expenses | $3.15M | $1.85M | $6.58M | $4.32M |
| Cash & Equivalents (End of Period) | $6.12M | $10.04M | $6.12M | $10.04M |
| Accumulated Deficit | $(126.10)M | $(103.69)M | $(126.10)M | $(103.69)M |
| Debt (Note Payable) | $3.18M (Current) | $2.53M (Current) | $3.18M (Current) | $2.53M (Current) |
Note: Comparative 2024 figures have been restated to correct an accounting error regarding the classification of derivative instruments.
Material Changes vs. Prior Period
- Increased Operating Expenses: Net loss increased 77.9% in Q3 2025 compared to Q3 2024. R&D expenses rose 99.5% and G&A expenses rose 69.7%.
- R&D Drivers: Increases attributed to personnel costs (including executive separation costs and a contingent bonus accrued upon NDA submission), manufacturing costs for process validation batches, and regulatory fees.
- G&A Drivers: Increases driven by personnel costs (contingent bonus) and commercial costs related to a new partnership with Indegene.
- Cash Burn: Cash and cash equivalents decreased by approximately $6.1 million during the nine months ended September 30, 2025, compared to an increase of $10.0 million in the same period in 2024. Net cash used in operating activities was $13.65 million for the nine months ended September 30, 2025.
- Debt Restructuring: The Company exchanged $2.475 million of principal on its Streeterville Capital promissory note for 594,487 shares of common stock during the quarter.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: The Company has substantial doubt about its ability to continue as a going concern for one year from the filing date. With $6.1 million in cash as of September 30, 2025, and a subsequent $6.0 million debt issuance in November 2025, management believes funds will last into Q2 2026. Approximately $9 million in additional capital is needed to reach the May 31, 2026 PDUFA date.
- Recent Financing: On November 7, 2025, the Company issued a $6.57 million unsecured promissory note to Avondale Capital, LLC, receiving $6.0 million in cash proceeds. The note bears 9% interest and matures in 18 months.
- Management Changes:
- Shane Schaffer (Chairman and CEO) was placed on administrative leave in August 2025 following criminal charges (later amended to a misdemeanor). Jennifer Callahan (CFO) serves as Interim CEO, and John A. Roberts serves as Executive Chairman.
- Bryan Downey was hired as Chief Commercial Officer in November 2025.
- Regulatory Risks: Potential government shutdowns (noted as beginning October 1, 2025) could delay FDA review of the CTx-1301 NDA.
- Accounting Correction: The Company corrected an error in prior periods regarding the Lincoln Park Purchase Agreement, reclassifying certain costs from equity to expense, which increased reported net losses for comparative periods.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $12.1 million total cash position (including Nov 2025 debt proceeds) to fund operations through the May 2026 PDUFA date without further dilution or debt.
- Debt Covenants: Review the terms of the Streeterville and Avondale promissory notes, specifically regarding redemption schedules, monitoring fees, and restrictions on future equity issuances.
- Management Stability: Assess the impact of the CEO's legal proceedings and administrative leave on strategic execution and investor confidence.
- Commercialization Readiness: Evaluate the status of the commercial supply agreement with CoreRx and the partnership with Indegene for the potential launch of CTx-1301.
- Restatement Impact: Confirm understanding of the accounting error correction and its effect on year-over-year loss comparisons.